Your browser is no longer supported. Please, upgrade your browser.
XOMA XOMA Corporation daily Stock Chart
XOMA Corporation
Index- P/E- EPS (ttm)-0.96 Insider Own0.10% Shs Outstand10.82M Perf Week-2.68%
Market Cap210.09M Forward P/E- EPS next Y-0.56 Insider Trans- Shs Float10.41M Perf Month5.61%
Income-9.40M PEG- EPS next Q-0.21 Inst Own63.10% Short Float6.62% Perf Quarter9.02%
Sales10.50M P/S20.01 EPS this Y85.80% Inst Trans2.39% Short Ratio21.17 Perf Half Y-18.59%
Book/sh3.55 P/B5.52 EPS next Y58.20% ROA-10.40% Target Price29.50 Perf Year6.07%
Cash/sh4.61 P/C4.24 EPS next 5Y19.00% ROE-25.30% 52W Range14.14 - 28.85 Perf YTD-28.28%
Dividend- P/FCF- EPS past 5Y49.80% ROI-5.10% 52W High-32.13% Beta0.91
Dividend %- Quick Ratio4.60 Sales past 5Y-0.50% Gross Margin- 52W Low38.47% ATR1.17
Employees11 Current Ratio4.60 Sales Q/Q-60.00% Oper. Margin-94.10% RSI (14)47.87 Volatility6.51% 5.80%
OptionableNo Debt/Eq0.81 EPS Q/Q30.10% Profit Margin-89.60% Rel Volume0.31 Prev Close19.86
ShortableYes LT Debt/Eq0.61 Earnings- Payout- Avg Volume32.56K Price19.58
Recom2.00 SMA20-0.57% SMA500.47% SMA200-7.04% Volume10,182 Change-1.41%
Jan-18-18Reiterated H.C. Wainwright Buy $38 → $49
Oct-17-17Resumed H.C. Wainwright Buy $38
Sep-05-17Upgrade Wedbush Neutral → Outperform $9 → $19
Jun-12-17Initiated H.C. Wainwright Buy $15
Nov-14-16Downgrade Wedbush Outperform → Neutral $17 → $14
Mar-11-16Reiterated Wedbush Outperform $6 → $3
Jul-23-15Downgrade Jefferies Buy → Hold
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-22-15Downgrade Ladenburg Thalmann Buy → Neutral
Oct-10-14Resumed ROTH Capital Buy $9
Apr-29-14Upgrade MLV & Co Hold → Buy $7
Mar-11-14Downgrade MLV & Co Buy → Hold $8 → $7
Mar-05-14Reiterated Ladenburg Thalmann Buy $6.50 → $10
Oct-31-13Reiterated MLV & Co Buy $7.50 → $8
May-09-13Reiterated Ladenburg Thalmann Buy $5 → $6
May-14-12Initiated Cowen & Co Outperform
Mar-31-11Reiterated MLV Capital Buy $12 → $10
Mar-23-11Reiterated RBC Capital Mkts Outperform $8 → $6
Jan-06-11Reiterated Ladenburg Thalmann Buy $12 → $16
Jan-04-11Reiterated Wedbush Outperform $12 → $16
Oct-14-20 07:30AM  
Sep-23-20 12:15PM  
Sep-10-20 11:18AM  
Sep-02-20 07:30AM  
Aug-17-20 07:19AM  
Aug-06-20 07:50PM  
Aug-05-20 07:30AM  
Jul-28-20 12:33PM  
Jul-01-20 07:30AM  
Jun-29-20 07:30AM  
Jun-24-20 11:00PM  
Jun-22-20 01:58PM  
May-11-20 01:42PM  
May-05-20 09:45AM  
Apr-28-20 12:39PM  
Apr-27-20 12:31PM  
Mar-13-20 10:53AM  
Mar-10-20 07:30AM  
Mar-09-20 05:00AM  
Feb-27-20 12:30PM  
Feb-25-20 04:30PM  
Jan-22-20 01:02PM  
Dec-26-19 07:12AM  
Dec-23-19 04:00PM  
Dec-20-19 04:35PM  
Dec-16-19 09:34AM  
Dec-05-19 05:04PM  
Dec-02-19 04:30PM  
Nov-19-19 04:30PM  
Nov-13-19 06:47AM  
Nov-05-19 08:20AM  
Oct-30-19 10:33AM  
Oct-15-19 03:39PM  
Sep-27-19 07:56AM  
Sep-26-19 04:07PM  
Sep-12-19 01:37PM  
Sep-03-19 08:00AM  
Aug-13-19 08:30AM  
Aug-12-19 07:30AM  
Aug-06-19 10:05AM  
Jul-30-19 03:16PM  
Jul-09-19 02:07PM  
Jun-13-19 06:45AM  
Jun-07-19 09:25AM  
May-06-19 07:55PM  
May-01-19 10:33AM  
Apr-12-19 05:20PM  
Apr-11-19 12:14PM  
Apr-08-19 06:00AM  
Apr-03-19 07:00AM  
Mar-07-19 07:05AM  
Mar-05-19 07:00AM  
Feb-21-19 05:48PM  
Feb-13-19 07:00AM  
Feb-04-19 07:28AM  
Jan-03-19 04:35PM  
Dec-18-18 04:43PM  
Nov-19-18 04:30PM  
Nov-07-18 11:55AM  
Oct-30-18 08:05AM  
Oct-29-18 10:31AM  
Oct-25-18 08:15AM  
Sep-27-18 04:30PM  
Sep-24-18 12:15PM  
Sep-21-18 07:00AM  
Aug-28-18 07:00AM  
Aug-09-18 07:00AM  
Aug-07-18 06:15PM  
Jun-26-18 07:00AM  
May-15-18 07:00AM  
May-09-18 06:11PM  
May-08-18 07:00AM  
May-02-18 07:30AM  
Apr-03-18 07:00AM  
Mar-20-18 07:35AM  
Mar-07-18 05:46PM  
Mar-05-18 07:00AM  
Feb-19-18 10:04AM  
Feb-16-18 09:56AM  
Feb-14-18 05:48PM  
Feb-08-18 11:26AM  
Feb-06-18 10:00AM  
Feb-02-18 10:00AM  
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BVF PARTNERS L P/ILDirectorSep 23Buy18.2017,089311,0162,040,124Sep 23 07:26 PM
BVF PARTNERS L P/ILDirectorSep 22Buy18.4511,951220,4452,030,236Sep 23 07:26 PM
BVF PARTNERS L P/ILDirectorSep 21Buy18.3922,328410,5032,023,276Sep 23 07:26 PM
BVF PARTNERS L P/ILDirectorSep 04Buy18.777,737145,2282,011,017Sep 10 08:10 AM
BVF PARTNERS L P/ILDirectorSep 01Buy18.8717,572331,5152,007,110Sep 01 08:37 PM
BVF PARTNERS L P/ILDirectorAug 31Buy18.4816,005295,7821,997,210Sep 01 08:37 PM
BVF PARTNERS L P/ILDirectorAug 28Buy19.172,04439,1871,988,067Sep 01 08:37 PM
BVF PARTNERS L P/ILDirectorAug 25Buy19.755,687112,2901,986,945Aug 25 08:10 PM
BVF PARTNERS L P/ILDirectorAug 24Buy19.3111,683225,5911,983,502Aug 25 08:10 PM
BVF PARTNERS L P/ILDirectorAug 21Buy19.3210,805208,7701,976,998Aug 25 08:10 PM
BVF PARTNERS L P/IL10% OwnerAug 20Buy19.121,77233,8811,967,800Aug 20 06:56 PM
BVF PARTNERS L P/IL10% OwnerAug 19Buy19.703,49668,8771,966,028Aug 20 06:56 PM
BVF PARTNERS L P/IL10% OwnerAug 18Buy19.2789517,2461,962,532Aug 20 06:56 PM
BVF PARTNERS L P/IL10% OwnerAug 14Buy18.6921,922409,8101,961,637Aug 14 06:38 PM
BVF PARTNERS L P/IL10% OwnerAug 13Buy17.801,05018,6931,939,715Aug 14 06:38 PM
BVF PARTNERS L P/IL10% OwnerAug 12Buy17.344,05070,2331,938,665Aug 14 06:38 PM
BVF PARTNERS L P/IL10% OwnerMar 25Buy17.208,264142,1291,278,656Mar 27 08:29 PM
Neal James RCEOMar 23Buy14.501,00014,50020,849Mar 24 04:38 PM
Neal James RCEOMar 20Buy16.411,00016,41019,849Mar 23 04:30 PM
BVF PARTNERS L P/IL10% OwnerMar 18Buy14.524,43964,4751,270,392Mar 20 04:52 PM
BVF PARTNERS L P/IL10% OwnerMar 17Buy15.738,113127,6481,265,953Mar 17 09:30 PM
BVF PARTNERS L P/IL10% OwnerMar 16Buy15.7310,164159,9161,257,840Mar 17 09:30 PM
BVF PARTNERS L P/IL10% OwnerMar 13Buy18.34100,0001,834,0901,247,676Mar 17 09:30 PM
BVF PARTNERS L P/IL10% OwnerDec 19Buy22.00373,1958,210,2901,147,676Dec 20 07:18 PM
Neal James RCEONov 06Option Exercise5.504,34823,91422,017Nov 08 04:30 PM
Neal James RCEONov 06Sale22.004,34895,65617,669Nov 08 04:30 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.